170730-06-0

Basic information

• Product Name: 7-Acetyl-2,3-dihydrobenzofuran
• Synonyms: 7-Acetyl-2,3-dihydrobenzofuran;Ethanone, 1-(2,3-dihydro-7-benzofuranyl)- (9CI);1-(2,3-dihydrobenzofuran-7-yl)ethanone;Ethanone, 1-(2,3-dihydro-7-benzofuranyl);1-(2,3-Dihydro-7-benzofuranyl)ethanone;1-(2,3-Dihydro-7-benzofuranyl)
• CAS NO: 170730-06-0
• Molecular Formula: C₁₀H₁₀O₂
• Molecular Weight: 162.19
• Product Categories: ACETYLGROUP
• Mol File: 170730-06-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 294.989 °C at 760 mmHg
• Flash Point: 139.685 °C
• Appearance: /
• Density: 1.149 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.557
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 7-Acetyl-2,3-dihydrobenzofuran(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Acetyl-2,3-dihydrobenzofuran(170730-06-0)
• EPA Substance Registry System: 7-Acetyl-2,3-dihydrobenzofuran(170730-06-0)

Safety Data

• Hazardous Substances Data: 170730-06-0(Hazardous Substances Data)

Usage

Description

7-Acetyl-2,3-dihydrobenzofuran, also known as 1-(2,3-Dihydro-7-benzofuranyl)ethanone, is an organic compound that is commonly found as an impurity in the synthesis of Darifenacin, a medication used to treat urinary incontinence. It is characterized by its unique chemical structure, which consists of a benzofuran ring with a 2,3-dihydro substitution and an acetyl group attached to the 7-position.

Uses

Used in Pharmaceutical Industry:
7-Acetyl-2,3-dihydrobenzofuran is used as an impurity in the synthesis of Darifenacin for the treatment of urinary incontinence. Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which helps to reduce the frequency and urgency of urination.
In the synthesis process, the presence of 7-Acetyl-2,3-dihydrobenzofuran as an impurity may affect the purity and efficacy of the final product, Darifenacin. Therefore, it is essential to monitor and control the levels of this impurity during the manufacturing process to ensure the safety and effectiveness of the medication.

InChI:InChI=1/C10H10O2/c1-7(11)9-4-2-3-8-5-6-12-10(8)9/h2-4H,5-6H2,1H3

Upstream product

• 35700-40-4 2,3-dihydrobenzofuran-7-carboxylic acid 
• 917-54-4 methyllithium 
• 123266-63-7 2,3-Dihydro-7-benzofurancarboxylic acid chloride 
• 1037763-65-7 N-methoxy-N-methyl-2,3-dihydrobenzofuran-7-carboxamide 
• 75-16-1 methylmagnesium bromide 

Relevant articles and documents

Vascular endothelial growth factor receptor inhibitor and preparation method and application thereof

The invention provides a vascular endothelial growth factor receptor inhibitor and a preparation method and application thereof, and relates to a quinoline or quinazoline derivative with a structure as shown in a formula (I), a pharmaceutical composition containing a compound as shown in the formula (I) and application of the compound in preparation of drugs for preventing or treating angiogenesis-related diseases, in particular to prevention or treatment of tumors related to protein tyrosine kinase. Each substituent in the formula (I) is the same as the definition in the specification.

The selective 5-HT(1B) receptor inverse agonist 1-methyl-5-[[2'-methyl- 4'(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7- tetrahydrospiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function bo

5-HT1 receptors are members of the G-protein-coupled receptor superfamily and are negatively linked to adenylyl cyclase activity. The human 5-HT(1B) and 5-HT(1D) receptors (previously known as 5-HT(1Dβ) and 5- HT(1Dα), respectively), although e